Navigation Links
Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer
Date:5/30/2008

Woodcliff Lake, N.J., May 15, 2008The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy, said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine.

About Study 211 Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients received a median of four cycles of eribulin mesylate (range 1-27). No premedication to prevent hypersensitivity was required.

Two-hundred sixty-n
'/>"/>

Contact: Judee Shuler
201-746-2241
Eisai Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UM coral scientist Peter Glynn wins award for scholarly activity
2. Blood pressure drug telmisartan shows powerful activity against stroke
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
5. Cell-based therapy shows promise in patients with Parkinsons disease
6. Scientists test device to track medication adherence in patients with HIV/AIDS
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
9. Pregnant patients lose out in breast cancer treatment; a new approach is needed
10. Mental stress reduces blood flow to the heart in patients with gene variation
11. 2 new therapies show promise for cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... votes for independence later this week, its Government could ... that fracking is necessary, research has revealed. , The ... public perception of shale gas extraction in the UK ... north of the border are the least supportive of ... in the University,s School of Geography, said: "The clear ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... million gallons of oil into Alaska,s Prince William Sound. ... in the Gulf of Mexico in 2010. According to ... Research , news coverage of environmental disasters serves to ... the way fossil fuels are used. , "We found ... events helped to resolve many of the cultural anxieties ...
Breaking Biology News(10 mins):Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2
... a mission to sniff out trouble and display their ... of Naval Research (ONR)-hosted "Top Dog Demo 2012." ... move through the battle space," said Lisa Albuquerque, program ... ONR,s Expeditionary Warfare and Combating Terrorism department. "Marines can ...
... high speed rail lines in China will be the topic ... Liu takes the stage at the annual 91st Transportation Research ... gathering in transportation, if not all of engineering, with upwards ... an expert in high speed rail lines and other transportation ...
... EAST LANSING, Mich. -- A receptor found on blood platelets ... questioned may in fact be fruitful in drug testing, according ... team led by Dana Spence of MSU,s Department of Chemistry ... known as P2X1. By creating a new, simple method to ...
Cached Biology News:Marine's best friend shows explosive-detecting capabilities 2NJIT high speed rail expert to address DC conference next week 2NJIT high speed rail expert to address DC conference next week 3Chemists unlock potential target for drug development 2
(Date:9/16/2014)... September 16, 2014 Pharma ... to position themselves for their 89th year ... and encoding, Pharma Packaging Solutions is preparing ... and software and new procedures. Establishing training ... Manufacturing Practices (cGMP), Pharma Packaging Solutions will ...
(Date:9/16/2014)... Sept. 16, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... The full interim results will be presented at ... IGF Society, being held October 15-18, 2014, in ...
(Date:9/16/2014)... Australia (PRWEB) September 16, 2014 RENU 28, ... Signaling molecules, became available for purchase in Australia and ... a nationwide tour beginning September 16th. The tour will make ... the 17th, Bundaberg on the 18th, Sydney on the 20th, ... market in Australia and New Zealand and to educate people ...
(Date:9/15/2014)... , Sept. 15, 2014 EnGeneIC, ... revolutionizing the treatment of cancer through the targeted ... announced that, together with the Asbestos Disease Research ... Institute New South Wales (NSW) Premier,s Award for ... recipients are the hospitals that will be involved ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3
... DENVER, Nov. 18, 2010 BioSpace ... Campaign this morning, showcasing biotechnological, pharmaceutical ... States and Canada. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) ... campaign promotes life science organizations within Oregon, ...
... Inc. (OTCBB: GNLK ), a leading consumer genomics biotech company, today ... Highlights: Gross Profit Margin ... for the second year in a row GeneLink announces Private ... GeneLink,s CEO stated, "The third quarter of 2010 continues to reflect ...
... Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Biology Technology:BioSpace Highlights the Northwest's Growing Life Science Region 2GeneLink Reports Third Quarter Results 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
Presenilin-1, N-terminus....
Request Info...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: